Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital

Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Trajectory of Preserved Ratio Impaired Spirometry: Natural History and Long-Term Prognosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Chronic productive cough and inhalant occupational exposure-a study of the general population

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Occupational exposures and exacerbations of asthma and COPD-A general population study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Doxorubicin is a cornerstone in lymphoma treatment, but is limited by dose-dependent cardiotoxicity. Rubidium-82 positron emission tomography (82Rb PET) assesses coronary microvascular function through absolute quantification of myocardial perfusion and myocardial perfusion reserve (MPR). Doxorubicin-induced microvascular injury represents a potential early marker of cardiotoxicity.

METHODS AND RESULTS: We included 70 lymphoma patients scheduled for doxorubicin-based treatment. Cardiotoxicity was evaluated with 82Rb PET myocardial perfusion imaging during rest and adenosine stress before chemotherapy and shortly after the first doxorubicin exposure. Patients with a MPR decline > 20% were defined as having a low threshold for cardiotoxicity. In the 54 patients with complete data sets, MPR was significantly lower after the initial doxorubicin exposure (2.69 vs 2.51, P = .03). We registered a non-significant decline in stress perfusion (3.18 vs 3.02 ml/g/min, P = .08), but no change in resting myocardial perfusion. There were 13 patients with a low cardiotoxic threshold. These patients had a significantly higher age, but were otherwise similar to the remaining part of the study population.

CONCLUSION: Decreases in MPR after initial doxorubicin exposure in lymphoma patients may represent an early marker of doxorubicin-induced cardiotoxicity. The prognostic value of acute doxorubicin-induced changes in MPR remains to be investigated.

TidsskriftJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Udgave nummer5
Sider (fra-til)1698-1707
Antal sider10
StatusUdgivet - okt. 2020

ID: 55722251